FDA Panel To Review OSI Pharma's Tarceva As First-line Maintenance Therapy In Advanced Non-small Cell Lung Cancer

OSI Pharmaceuticals Inc. (OSIP) said that the FDA's advisory committee will review the use of Tarceva as a first-line maintenance therapy for patients with advanced non-small cell lung cancer who have not progressed following first-line treatment with platinum-based chemotherapy at its December 16 meeting.

Tarceva is the only oral, non-chemotherapy agent shown to provide a statistically significant improvement in both progression-free survival and overall survival in the NSCLC maintenance setting.

The FDA Prescription Drug Fee Act review date for the Tarceva application is on or about January 18, 2010.

For comments and feedback contact: editorial@rttnews.com

Follow RTT